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a b s t r a c t
Exosomes are extracellular vesicles (EVs) that play a role in intercellular communication. Stimulation of
dendritic cells by the HIV-1 virus triggers their release. HIV-1 binds to dendritic cells via dendritic cell
immunoreceptor (DCIR). This study shows that inhibiting the binding to DCIR signiﬁcantly decreases
exosome release by HIV-1-pulsed dendritic cells. In addition, exosome release from Raji-CD4 expressing
DCIR cells stimulated by anti-DCIR or HIV-1 is decreased when the immunoreceptor tyrosine-based
inhibition motif (ITIM) signaling motif of DCIR is mutated. Unlike the EVs released from Raji-CD4-DCIR
cells after antibody stimulation, those released from HIV-1-infected cells contain the pro-apoptotic
protein DAP-3. Furthermore, EVs from HIV-1 pulsed dendritic cells increase spontaneous apoptosis in
uninfected CD4 T lymphocytes while they decrease it in neutrophils. This study describes for the ﬁrst
time that DCIR plays a role in the release of exosomes strengthening the importance of this receptor and
EVs/exosomes in HIV-1 pathogenesis.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The human immunodeﬁciency virus type 1 (HIV-1) is known to
compromise immune defenses and lead to chronic diseases often
resulting in death. The progression of HIV-1 infection towards
AIDS is characterized by continuous elimination of infected CD4 T
lymphocytes (CD4TL), insufﬁcient renewal of circulating CD4TL as
a result of thymic dysfunction, inﬂammatory damage to other
lymphoid tissues (Douek et al., 1998; Elsasser et al., 2004), TGF-β-
mediated ﬁbrosis in lymph nodes (Banerjee et al., 2007; Schacker
et al., 2002), and abnormal retention and hence reduced migration
of effector-type T cells (Brenchley et al., 2004). This pathology is
also associated with chronic systemic immune activation, includ-
ing polyclonal activation of B cells (Moir and Fauci, 2009),
dysregulation of neutrophil and macrophage functions (d’Ettorre
et al., 2002; Roilides et al., 1990), increased T-cell activation
(Hazenberg et al., 2000), and increased serum concentrations of
pro-inﬂammatory cytokines and chemokines (Valdez and
Lederman, 1997). HIV-infected individuals exhibit histological
abnormalities in the gastrointestinal mucosa, malabsorption and
lymphocyte depletion (Kotler et al., 1993). Several studies have
shown that CD4TL are depleted ﬁrst in the gastrointestinal tract
during the acute phase of infection (Brenchley et al., 2004;
Guadalupe et al., 2003). This is due to the virus itself (Arnoult
et al., 2003), to cytotoxic activity of CD8þ T cells (Sewell et al.,
2000) and to cytopathic effects associated with accumulation of
abortive HIV-1 reverse transcripts (Doitsh et al., 2010) or extra-
cellular vesicles (EVs) including exosomes (Lenassi et al., 2010;
Subra et al., 2011b).
EVs participate in intercellular communication by trans-
membrane signaling and vesicle-mediated cell-to-cell transfer of
membrane receptors, proteins, mRNA, and miRNA (Nazarenko
et al., 2013). Exosomes are EVs ranging from 30 to 100 nm in
diameter, originating in endocytic compartments and following
pathways of multivesicular bodies biosynthesis. They are produced
primarily by hematopoietic, epithelial and tumor cells (Buzas et al.,
2014; Robbins and Morelli, 2014). EVs or exosomes derived from B
lymphocytes and dendritic cells are involved in antigen presenta-
tion to immune cells by MHC-II (Raposo et al., 1996; Thery et al.,
2002a, 2002b, 1999). Those derived from dendritic cells are also
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involved in the development of immune tolerance (Peche et al.,
2003; Segura et al., 2005a, 2005b), and via co-stimulatory mole-
cules present on them, in activation of CD4TL (Thery et al., 2002a,
2002b). In some cases, they appear to contribute to the events
leading from HIV-1 infection to AIDS (Lenassi et al., 2010; Subra
et al., 2011b).
Early events in HIV-1 infection are major determinants of the
irreversible damage inﬂicted on the immune system (Haase, 2010,
2011) and of the progression of infection towards AIDS. Cell-free
virions do not penetrate genital epithelial cells efﬁciently, using
instead primarily dendritic cells to cross it (Steinman et al., 2003).
Dendritic cells internalize the virus and migrate to secondary
lymphoid organs where they communicate with cells of the innate
and adaptive immune systems (Cameron et al., 1992; Tsunetsugu-
Yokota et al., 1997). HIV-1 and dendritic cells interact during
primary infection via viral external envelope glycoprotein gp120
oligosaccharides and cell-bound mannose receptor (CD206), lan-
gerin (CD207), DC-SIGN (Geijtenbeek et al., 2000; Turville et al.,
2003) or dendritic cell immunoreceptor (DCIR) (Bloem et al.,
2014). Via their lectin receptors, dendritic cells internalize the
virus in late endosomes.
The DCIR is a membrane-bound glycoprotein, member of the C-
type lectin family. It is expressed on the surface of cells of the
myeloid lineage, including dendritic cells, neutrophils, monocytes
and macrophages, on B lymphocytes (Bates et al., 1999), CD4TL from
HIV-1 patients (Lambert et al., 2010) and on CD4 and CD8 T
lymphocytes of arthritic patients (Eklow et al., 2008). Previous
studies have shown that dendritic cells or apoptotic CD4TL bind
HIV-1 via DCIR and that this leads to both trans and cis infection of
CD4TL (Lambert et al., 2008, 2010). In addition, a series of DCIR
inhibitors of small molecular mass have been identiﬁed and shown
to inhibit HIV-1 interactions with dendritic and CD4TL cells (Lambert
et al., 2013). The DCIR structure includes an extracellular ligand-
binding domain consisting of a carbohydrate recognition domain
(CRD), EPS motif (Glu-Pro-Ser), neck domain, and an immunorecep-
tor tyrosine-based inhibition motif (ITIM) involved in intracellular
signaling and internalization (Drickamer, 1993; Kanazawa et al.,
2004; Richard et al., 2003). DCIR ITIM motif is involved in the
modulation of cellular responses (Kanazawa, 2007) and plays a role
in transducing signals that inhibit leukocyte activation mediated by
tyrosine phosphatases SHP-1 and SHP-2 (Richard et al., 2006).
Activation of DCIR by speciﬁc antibodies promotes its internalization
in endosomes, leading to inhibition of pro-inﬂammatory cytokine
synthesis (IL-12, TNF and IFN-α) induced by TLR9 and TLR8 activation
(Meyer-Wentrup et al., 2008, 2009).
Many physical and biochemical similarities between exosomes
and HIV-1 have been reported, as has the coincidence of exosome
dissemination with the capture and transfer of HIV-1 particles by
dendritic cells (Izquierdo-Useros et al., 2009). HIV-1 biogenesis and
release through the normal cell-encoded exosome or vesicle biogen-
esis pathway was ﬁrst suspected several years ago (Nguyen et al.,
2003; Pelchen-Matthews et al., 2004). In dendritic cells and macro-
phages, exosomes are formed by reverse budding inside endosomal
compartments called multivesicular bodies and released into the
extracellular environment by fusion of the latter with the cell
membrane (Pelchen-Matthews et al., 2004; Thery et al., 2002a,
2002b). The similarity between exosomes and viral particle budding
(Izquierdo-Useros et al., 2011; Ostrowski et al., 2010) suggests that
some sharing of the cellular machinery is involved. Some observa-
tions indicate that budding takes place mainly at CD81-, CD9- and
CD63-rich invaginated micro-domains in the plasma membrane,
which are similar to endosomal domains. Exosomes can contain
viral material, miRNA of TAR (Narayanan et al., 2013), Gag p17
(Columba Cabezas and Federico, 2013) or accessory proteins
(Lenassi et al., 2010). Presence of Nef in exosomes has been shown
to cause activation-induced death of resting peripheral blood
lymphocytes in vitro (Lenassi et al., 2010). It has also been shown
that HIV-1-loaded dendritic cells release exosomes that induce
apoptosis in CD4TL (Subra et al., 2011b).
Fusion of endosomal compartments with lysosomes allows
degradation of their content or, alternatively, biogenesis of intra-
luminal vesicles, which later merge with the plasma membrane to
release exosomes and/or virions. The latter process appears to lead
to trans infection of CD4TL (Izquierdo-Useros et al., 2010). At least
one recent study indicates that HIV-1 infection increases exosome
secretion by dendritic cells (Subra et al., 2011b). However, it is not
yet known if increased exosomes amount by HIV-1-infected cells
is DCIR-dependent. The aim of the present study was to examine
the involvement of DCIR and its signaling pathways in the release
of exosomes from HIV-1-infected cells into the extracellular
environment. Our results suggest signiﬁcant roles for DCIR and
the ITIM motif in exosome production and show that EVs and
exosomes released by HIV-1-infected cells can intervene in the
apoptosis pathway, with opposite effects on CD4TL and
neutrophils.
Results
Impact of the DCIR-directed inhibitor on exosome release by iMDDCs
Several inhibitors of binding to DCIR have been identiﬁed using
the 3-D structure of the receptor (Lambert et al., 2013). Among these,
we chose 1-methyl-4-[4-methyl p-NNO-azoxy] benzene (DCIR inhi-
bitor), known to bind to the EPS motif. We studied the impact of this
DCIR inhibitor on HIV-1 infection of iMDDCs. Panel A in Fig. 1 shows
that pre-incubating iMDDCs with 1, 5, 10 and 50 mM of inhibitor
decreases viral binding by about, respectively, 20%, 60%, 70% and 80%.
The impact of the DCIR inhibitor at a concentration of 10 mM is
signiﬁcant until 10 days post-infection (Fig. 1, panel B), without
affecting cellular viability as previously described (Lambert et al.,
2013) and illustrated in Supplementary Fig. 1.
We demonstrated in our previous studies that the exosome
release from iMDDCs is increased following HIV-1 cell pulsing and
that these exosomes have a deleterious effect on neighboring CD4TL
(Subra et al., 2011a, 2011b). However, the role of DCIR in exosome
release from HIV-1-pulsed-dendritic cells remains unknown. Based
on measurements of hydrodynamic size of nanoparticles using the
Zetasizer Nano-ZS, we conﬁrmed the presence of homogenous
vesicles with an average diameter of 100 nm, which match the
known size range of exosomes (see Supplementary data for a typical
example, Fig. 2). We quantiﬁed exosomes by measuring AChE activity
of velocity gradient fractions as described previously by us (Cantin
et al., 2008) (Fig. 2). We show that NL4-3Balenv increases exosome
release from iMDDCs, while pre-incubating them with the DCIR
inhibitor decreases this response. In order to validate the effect of the
DCIR inhibitor, we performed the test using a different R5-tropic
virus, NLAD8 (Supplementary data, Fig. 3). In conclusion, we conﬁrm
that the exosome release by dendritic cells is increased in the
presence of HIV-1 and is decreased when the cells are pre-treated
with the DCIR inhibitor.
In order to provide additional support for the link between
HIV-1, exosome release, DCIR and its signaling motif, exosomes
were collected from the extracellular medium after 5 days of
culture of Raji-CD4-DCIR cells exposed to NL4-3 virions. (Zetasizer
Nano-ZS analysis of our preparation quality is provided in Supple-
mentary Fig. 2). Based on results obtained by AChE assay, we show
that the contact with HIV-1 increases exosome release, while the
inhibitor suppresses this response (Fig. 3A). To determine whether
or not the ITIM signaling motif plays a role in HIV-1 binding, Raji-
CD4-DCIR with either normal ITIM motif or its mutant form
(tyrosine substituted for phenylalanine; cell-line designated as
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Raji-CD4-DCIR-Y7F) were exposed to NL4-3 treatment for 60 min,
washed and then incubated for 5 days. Based on AChE activity
results, we demonstrate that exosome release from the Raji-CD4-
DCIR-Y7F, ITIM-mutated cell-line, is decreased (Fig. 3B), suggesting
the involvement of the ITIM motif. (Supplementary Fig. 4 supports
the hypothesis that the inhibitor does not affect cellular metabo-
lism of Raji-CD4-DCIR and Raji-CD4-DCIR-Y7F cells and DCIR
inhibitor affect HIV-1 binding.) Raji-CD4-DCIR-Y7F cells have been
previously described to limit HIV-1 infection in comparison with
Raji-CD4-DCIR cells (Lambert et al., 2011) and result in Supple-
mentary Fig. 5 validate that the inhibitor affect only the HIV-1
binding and attachment on Raji-CD4-DCIR.
Stimulation with anti-DCIR antibody promotes exosome release from
Raji-CD4-DCIR cells
In order to validate the role of DCIR in exosome release, we
used an antibody to activate the receptor directly. Raji-CD4-DCIR
cells were exposed to anti-DCIR antibody or isotype-matched IgG
immobilized on assay plates. Supernatants were collected after
48 h, and exosomes recovered by differential centrifugation were
quantiﬁed by AChE assay (Fig. 4A). The increase in AChE activity
was signiﬁcant after two days contact with anti-DCIR antibody.
Cells incubated with DCIR inhibitor for 10 min prior to contact
with the immobilized antibody were less responsive to stimula-
tion by the antibody (Fig. 4A), as were the mutant Raji-CD4-DCIR-
Y7F cells (Fig. 4B). Since we already shown that inhibition of
phosphatases SHP-1 and SHP-2, Src family tyrosine kinase, tyr-
osine kinase Syk, serine/threonine kinases PKC or MAP, signiﬁ-
cantly reduced HIV-1 binding and infection via DCIR (Lambert
et al., 2011), we also pre-incubated cells with Src kinase inhibitor
PP2 for 10 min before the 48 h contact with the anti-DCIR anti-
body. A decrease in exosome release was observed (Fig. 4A). As
control for stimulation, results presented in the Supplementary
Fig. 6 illustrate the fact that stimulation of Raji-CD4-DCIR cells
with anti-DCIR antibody induces tyrosine kinase activation and
that inhibition of Src kinase with the PP-2 blocks this activation.
DAP-3 Is present only in EVs derived from HIV-1-stimulated cells
We have shown previously that HIV-1 induces release of
exosomes by immature and mature dendritic cells, but only those
from immature cells induce apoptosis in bystander CD4TL (Subra
et al., 2011b). Proteomic analysis of exosomes from immature
dendritic cells have revealed that exosomes from HIV-1-
stimulated cells are enriched in pro-apoptotic molecule DAP-3
(Subra et al., 2011b). Proteins in EVs derived from Raji-CD4-DCIR
cells were therefore stimulated with HIV-1 or anti-DCIR antibody
and examined in the hope of ﬁnding some distinctive character-
istic of EVs released following HIV-1-infection. Samples were
probed for the following proteins: LAMP-2 from endosomes,
ICAM-1 from plasma membranes, MHC-I and MHC-II present on
plasma membranes and/or endosomal membranes, and DAP-3, a
pro-apoptotic molecule contained in exosomes. Western blot
analysis showed clearly that EVs released from cells stimulated
with NL4-3 virus bear LAMP-2, as exosomes markers, in addition
to the pro-apoptotic protein DAP-3 (Fig. 5), as we have previously
assessed by proteomic analysis in other cell types (immature
dendritic cells: Subra et al., 2011b). ICAM-1, MHC-I and MHC-II
are not differentially expressed between samples, given the
observed data. ICAM-1, MHC-I and MHC-II indicate the presence
of EVs of plasma membrane origin, although these markers have
been found previously on viral particles (Cantin et al., 2005). The
results resumed in Figs. 3–5 support the assertion that stimulation
of DCIR is involved in exosome release and that their protein
content is their distinctive signature.
The role of EVs derived from HIV-1 infected cells in pathogenesis
We next investigated the effect of EVs released from HIV-1-
pulsed immature dendritic cells on both autologous neutrophils
and CD4TL viability. These two cell types are involved in early
events of HIV-1 pathogenesis and in the maintenance of mucosal
integrity. Puriﬁed EVs released from dendritic cells exposed to
NLAD8 virus for two days were added to suspensions of auto-
logous CD4TL or neutrophils. Apoptosis, measured after 24 h of
incubation at 37 1C using FITC-VAD-FMK staining, was increased in
CD4TL by 1.3-fold but had an equivalent decrease in neutrophils
(Fig. 6). This differential apoptotic effect of EVs on these two cell
types needs to be investigated more closely.
Discussion
In North America, the widespread availability of antiretroviral
treatment has signiﬁcantly reduced AIDS-related mortality. How-
ever, this treatment increases co-morbidity and fails to eradicate
the virus from the body, leading to selection of resistant viral
variants. Until an effective vaccine is developed, preventing infec-
tion or enhancing the speciﬁc immune response will remain the
Fig. 1. Impact of DCIR inhibitor on DCIR-speciﬁc HIV-1 infection. (A) iMDDCs were
treated for 10 min with DCIR inhibitor at 1–50 mM and then contacted with HIV-1
NL4-3Balenv for 60 min. Cells were then washed twice before lysis in hypotonic
lysis buffer. Virions attached to cells were quantiﬁed by measuring p24 content.
(B) iMDDCs were treated with DCIR inhibitor at 10 mM then exposed to NL4-
3Balenv for 2 h. Cells were then rinsed thoroughly and maintained in complete
culture medium supplemented with GM-CSF and IL-4 for up to 10 days, with
medium replenishment every three days. Cell-free culture supernatants were
assayed for p24 content. Cell culture and treatments were conducted at 37 1C.
Values are mean7SEM of at least three experiments. Asterisks denote statistically
signiﬁcant values (**Po0.01).
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best approach to limiting the spread and ravages of AIDS. In the
meantime, it would help immensely to minimize early damage to
the immune system. In order to achieve this, we must ﬁrst
increase our understanding of the pathological mechanisms of
the disease. Previous studies have shown that the lectin DCIR,
expressed primarily on dendritic cells, can bind HIV-1 and parti-
cipates in cis and trans infection of dendritic cells (Lambert et al.,
2008) as well as in trans infection of CD4TL (Lambert et al., 2010).
We have also observed previously that infection by HIV-1
increases exosome release from dendritic cells (Subra et al.,
2011b). The results obtained in the present study provide support
for the link between DCIR-associated signaling and EVs and
exosome release. It is particularly noteworthy that EVs derived
from infected cells induced apoptosis in CD4TL but not in neu-
trophils, two cell types involved in the perturbation of intestinal
homeostasis during primary infection.
It should be noted that during primary infection, HIV-1 uses
dendritic cells to cross the epithelial cells of the genital mucosa. Using
various membrane receptors including type C, DC-SIGN, MMR and
DCIR lectins, dendritic cells capture the virus in the mucous mem-
branes, internalize it in intracellular compartments (Geijtenbeek et al.,
2000; Lambert et al., 2008; Turville et al., 2003), where the virus is
protected from the immune system and thus migrates to the lymph
nodes, where large numbers of virions then infect CD4TL. Infected
CD4TL either undergo lysis or are destroyed by cytotoxic cells.
Furthermore, bystander cells also disappear during this primary
phase, possibly due to the action of secreted factors such as exosomes,
leading to progressive T cell depletion and contributing to the gradual
destruction of the immune system.
Characterization of the exosomes released following activation
of DCIR by anti-DCIR antibody or by binding of HIV-1, as shown in
this study, is of signiﬁcant importance to understanding HIV-1
pathogenesis. Activated DCIR is thus ﬁrst internalized in endo-
somes (Meyer-Wentrup et al., 2009), from which exosomes are
derived. In fact, exosomes are formed in late endosomes. Exosome
release can mediate important signaling events in the regulation
of the immune response, including the induction of tolerance (Kim
et al., 2006; Peche et al., 2006; Segura et al., 2005a, 2005b). The
potential role of DCIR activation in the induction of tolerance has
been described elegantly in the thesis of Dr. Bloem (http://www.
tipharma.com/ﬁleadmin/user_upload/Theses/PDF/Karien_Bloem_
T1-214.pdf) and, more recently, in Garcia-Vallejo et al., 2015. These
observations combined with those presented here point toward a
role for DCIR in mediating immune tolerance of HIV-1 and possibly
other retroviruses that exploit the same pathway. In other words,
interaction of HIV-1 with DCIR can contribute to weakening the
speciﬁc immune response to virions. Blocking it could therefore
help to promote the speciﬁc immune response.
Our results also indicate that contact between DCIR on dendritic
cells and HIV-1 promotes extracellular accumulation of exosomes.
Even more interesting is that EVs from HIV-1-infected cells contain
DAP-3, well known pro-apoptotic protein, while EVs from cells
stimulated with anti-DCIR antibody do not. Our demonstration that
EVs derived from HIV-1-infected cells can induce apoptosis in
bystander cells corroborates previous observations that exosomes
AChEþ they do so in T cells (Subra et al., 2011b). Decreasing EVs
and exosome release might then reduce the harm caused by them in
the context of HIV-1 infection, including the deleterious effects on
neighboring CD4TL. Accordingly, the inhibition of exosome release
from dendritic cells stimulated by binding HIV-1 could contribute to
limiting the bystander effect of HIV-1 infection.
We also demonstrated the involvement of the ITIM motif in the
DCIR-associated signaling that leads to exosome release. When the
tyrosine portion of the motif is replaced with a phenylalanine
residue, smaller amounts of exosomes are released.
Given the similarity of the exosome biogenesis pathway to viral
particle assembly in the intracellular compartments, and to the channels
of viral dissemination in the trans infection process (Izquierdo-Useros
Fig. 2. Impact of DCIR inhibitor on exosome release by HIV-1-loaded cells. iMDDCs (1106 cells/ml) were treated with 10 mM of DCIR inhibitor or DMSO for 10 min and then
for 2 h either contacted with HIV-1 NL4-3Balenv virus (100 ng/106 cells) or subjected to the mock treatment. After three washes with PBS to remove non-adsorbed virus, cells
were incubated for 48 h at 37 1C, at 1106 cells/ml in 6-well plates in RPMI 1640 supplemented with GM-CSF and IL-4. Released exosomes were puriﬁed as described in
Materials andmethods by sequential centrifugation and quantiﬁed by measuring AChE activity in the 100,000g pellet (A) or in each Optiprep velocity gradient fraction (B–D).
Values are mean7SEM of at least three (A) or ﬁve (B–D) independent experiments. (Signiﬁcant differences: ***Po0.001, **Po0.01, *Po0.05).
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et al., 2009), we have shown that DCIR-dependent signaling pathways
are involved in HIV-1 binding to, entry into and infection of cells, and
are also involved in the increase in exosome release into the extra-
cellular environment. This correlation has been observed for SHP-1,
SHP-2, tyrosine kinase Syk, the Src family (Src, Fyn and Hck), and PKC
and MAP kinases (p38 and Erk1/2), all of which play an important role
in the induction of DCIR signaling after binding HIV-1 or antibodies
stimulation (Supplementary Fig. 6). Using the Src kinase inhibitor PP2,
we observed a reduction in exosome release from cells that express
DCIR. Src kinase could be the ﬁrst enzyme involved in the signaling
cascade following its recruitment to the membrane via its myristoyla-
tion domain.
The speciﬁcity of the inhibitory effect for endosomal trafﬁcking was
tested in a DCIR-independent system, namely internalizing of green-
ﬂuorescence-protein-coupled bradykinin receptor (B2R-GFP) upon sti-
mulation by an agonist and subsequent recycling to the plasma
membrane. As previously reported (Charest-Morin et al., 2013), pacli-
taxel selectively inhibits agonist-induced internalization of B2R-GFP and
cytochalasin D interferes with recycling, while DCIR inhibitor was found
not to interfere with this system (Supplementary data, Fig. 7). The
demonstration that our DCIR inhibitor does not affect other endosomal
pathways suggests strategies for lessening the likelihood of HIV-1
infection in high-risk individuals. Using non-speciﬁc means of blocking
endocytosis could decrease antigenic presentation and consequently the
development of effective immune response. In contrast, blocking DCIR
speciﬁcally could reduce exosome production as well as increase the
speciﬁc immune response and decrease tolerance.
Finally, we showed that EVs and exosomes released from HIV-
1-infected dendritic cells increase apoptosis in CD4TL, which
might explain in part why these cells are selectively depleted in
models of gut-associated lymphoid tissue (GALT) (Ancuta et al.,
2010; Favre et al., 2009; Monteiro et al., 2011). CD4TL-polarized-
Th17 play a crucial role in mucosal antimicrobial immunity and
tissue homeostasis. This T-cell subset is known to contribute to the
recruitment of neutrophils (Ye et al., 2001) which produce anti-
microbial and anti-HIV-1 molecules such as defensins (Chang and
Klotman, 2004; Chang et al., 2005; Wu et al., 2005), and remove
bacteria and products thereof by phagocytosis (Dobmeyer et al.,
1995). Neutrophils in GALT appear to slow the progression of HIV-
1 pathogenesis by opposing microbial translocation (Ancuta et al.,
2008; Brenchley et al., 2006). Furthermore, the ability of neutro-
phils to undergo rapid apoptosis is important for the resolution of
inﬂammation (El Kebir and Filep, 2010; El Kebir et al., 2012;
McGrath et al., 2011), and our present results indicate that
exosomes released from HIV-1-infected cells likely interfere with
this process.
Conclusion
In summary, our results indicate that activation of DCIR by anti-
DCIR antibody or HIV-1 promotes the release of exosomes from
dendritic cells and other DCIR-bearing cells and that the ITIM
motif plays a role in this activation. Furthermore, EVs released
from HIV-1-infected cells bear at least one pro-apoptotic protein
and appear to increase apoptosis of CD4TL while they decrease it
in neutrophils. We have thus shed modest new light on the role of
exosomes and EVs in the pathological developments that occur
during HIV-1 primary infection, and thereby provide additional
support for the possibility of clinical beneﬁt resulting from
neutrophil function maintained by inhibiting EVs or exosome
Fig. 3. Exosomes are released by HIV-1-infected Raji-CD4-DCIR cells. (A) Raji-CD4-
DCIR cells were treated with DCIR inhibitor (10 mM) for 10 min and then, for
60 min, either contacted with HIV-1 NL4-3 virus or subjected to the mock
treatment. The microvesicle fraction was collected after 5 days. Exosomes were
puriﬁed as described in Materials and methods by sequential centrifugation and
quantiﬁed by measuring AChE activity. (B) Raji-CD4-DCIR or Raji-CD4-DCIR-Y7F
cells were contacted with HIV-1 NL4-3 virus or subjected to the mock treatment as
described above. Exosomes were puriﬁed by centrifugation and quantiﬁed by
measuring AChE activity. Values are mean7SEM of at least three independent
experiments. (Signiﬁcant differences: ***Po0.001, *Po0.05)
Fig. 4. Exosome release from cells stimulated with anti-DCIR antibody: (A) Raji-
CD4-DCIR cells were treated with DCIR inhibitor (10 mM) or Src inhibitor (PP-2)
(10 mM) for 10 min at 37 1C prior to incubation in assay plates coated with 30 mg of
monoclonal anti-DCIR antibody. The AChE activity in the 100,000 g pellet (obtained
as described in Materials and methods) was measured after 48 h at 37 1C. (B) Raji-
CD4-DCIR or Raji-CD4-DCIR-Y7F cells were stimulated with anti-DCIR antibody as
described above. Exosomes were then puriﬁed by centrifugation and quantiﬁed by
measuring AChE activity, as described in Materials and methods. Values are
mean7SEM of at least three independent experiments. (Signiﬁcant differences:
**Po0.01, *Po0.05)
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release at this stage of HIV-1 infection. Further studies are
required in order to determine the impact of exosome release
and inhibition of binding to DCIR in vivo and their clinical impact
on the progression of HIV-1 infection.
Materials and methods
Reagents
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was
purchased from GenScript (Picataway, NJ). Human recombinant IL-2
(rhIL-2) was obtained through the AIDS Repository Reagent Program
(Germantown, MD). IL-4 was purchased from R&D Systems Inc.
(Minneapolis, MN). Primocin, plasmocin and G418 were purchased
from InvivoGen (San Diego, CA). RPMI 1640, Lymphocyte Separation
Medium, fetal bovine serum (FBS), penicillin G, streptomycin and L-
glutamine were purchased from Wisent Inc. (Saint-Bruno, QC, Canada).
α-MEM and geniticin were purchased from Life Technologies (Burling-
ton, ON, Canada). Phytohemagglutinin-L (PHA-L), acetylthiocholine, 5,5-
dithio-bis(2-nitrobenzoic acid), 2,20-dithiodipyridine (AT-2), Optiprep™
(60% iodixanol), thiazolyl blue tetrazolium bromide (MTT), dextran,
paclitaxel and cytochalasin D were all purchased from Sigma-Aldrich
(St. Louis, MO). Tyrosine kinase inhibitor PP2 (Src family) was purchased
from Calbiochem (San Diego, CA). Bradykinin (BK) was purchased from
Bachem (Torrance, CA). The DCIR inhibitor 1-methyl-4-[4-methylphe-
nyl-NNO-azoxy] benzene, designated as compound B2 in (Lambert
et al., 2013)was purchased from ChemBridge (San Diego, CA).
Antibodies
Monoclonal mouse anti-human DCIR antibody (clone 216110)
and the corresponding control isotype immunoglobulin G (IgG)
were purchased from R&D Systems Inc. (Minneapolis, MN). When
necessary, antibodies were puriﬁed using mAbTrap protein afﬁnity
columns according to the manufacturer's instructions (Pharmacia
Technology AB, Uppsala, Sweden). Anti-HLA-DRα (DA6.147), anti-
ICAM-1 (G-5), anti-MHC-I (F-3) and anti-LAMP-2 (H4B4) were
purchased from Santa Cruz Biotechnologiess Inc. (Santa Cruz, CA).
Anti-DAP-3 was obtained from BD Biosciences (Mississauga, ON,
Canada). HRP-conjugated donkey anti-mouse secondary antibody
and F(ab')2 fragment goat anti-mouse F(ab')2 speciﬁc antibody
were obtained from Jackson Immunoresearch (Baltimore, MA). For
the HIV-1 p24 enzyme-linked immunosorbent assay (ELISA), the
Fig. 5. Characterization of protein content in the 100,000 g pellet. (A) Raji-CD4-DCIR cells were either contacted with HIV-1 NL4-3 virus or subjected to the mock treatment
for 2 h. The microvesicle fraction was collected after 5 days and puriﬁed by sequential centrifugation as described in Materials and methods. Microvesicle proteins were
analyzed by immunoblot. These results are representative of three independent experiments. (B) Raji-CD4-DCIR cells were contacted with anti-DCIR antibody and the
microvesicle fraction was collected after two days and puriﬁed by sequential centrifugation as described in Materials and methods. Immunoblots were performed on the
100,000g pellet. These results are representative of two independent experiments.
Fig. 6. Non-infectious particles released from HIV-1-loaded iMDDC differentially
modulate apoptosis in CD4TL and neutrophils. iMDDCs (3106 cells) were
contacted with NLAD8 virus produced on HEK 293 T for 2 h and then washed.
The pulsed cells were incubated for two days. Supernatants were collected and
exosomes were puriﬁed as described in Materials and methods. CD4TLPHA-L/IL-2
activated cell or neutrophils were incubated for 24 h with exosomes and non-
infectious HIV-1 AT-2 treated particles obtained from the centrifugal pellet
(100,000g). FITC-VAD-FMK was added 30 min before ﬂow cytometry. Results are
expressed as percentage of cells positive for FITC-VAD-FMK and are based on a
representative donor from each of two independent experiments.
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capture anti-p24 (hybridoma 183-H12-5C) and the detection
biotin-conjugated anti-p24 (hybridoma 31–90-25) antibodies
were used. Both were obtained through the AIDS Repository
Reagent Program (Germantown, MD). Streptavidin-PolyHRP40
was purchased from Fitzgerald Industries (Burlington, ON,
Canada).
Cells
Primary human blood cells were obtained from anonymous
healthy volunteer donors who had signed an informed consent form
approved by the CHU de Québec research ethics review board. Venous
blood was obtained in isocitrate anticoagulant solution. Neutrophils
were separated as described previously (Gilbert et al., 2003). Brieﬂy,
whole blood was centrifuged at 180g for 10 min and the resulting
platelet-rich plasma was discarded. Leukocytes were obtained follow-
ing sedimentation in 2% dextran. Mononuclear cells were removed by
centrifugation on Lymphocyte Separation Medium cushion and ery-
throcytes in the neutrophil pellets were lysed by 15 s contact with
hypotonic buffer. Neutrophils were resuspended at 107 cells/ml in
RPMI medium supplemented with 10% FBS. Human immature
monocyte-derived dendritic cells (iMDDCs) and CD4TL were isolated
from peripheral blood mononuclear cells and generated from mono-
cytes (i.e. CD14þ cells) as described previously (Gilbert et al., 2007).
Peripheral blood mononuclear cells were prepared by centrifugation
on Lymphocyte Separation Medium layer. CD14þ cells were then
isolated using a monocyte-positive selection kit according to the
manufacturer's instructions (StemSep Human CD14 Positive Selection
Kit, STEMCELL Technologies Inc., Vancouver, BC, Canada) using an
autoMACSs (Miltenyi Biotec). CD14þ cells were cultured in 6-well
plates at a concentration of 106 cells/ml to generate iMDDCs. Puriﬁed
monocytes were incubated in complete culture medium supplemen-
ted every 2 days with GM-CSF (1000 U/ml) and IL-4 (200 U/ml) for 6–
7 days. Experiments were performed with dendritic cell preparations
495% pure and with CD4þ T cell preparations 498% pure. T cells
were puriﬁed from peripheral blood by two rounds of negative
selection using magnetic beads from STEMCELL Technologies (Van-
couver, BC, Canada) according to the manufacturer's instructions. All
primary human blood cells lines were cultured in RPMI 1640 medium
supplemented with 10% FBS, penicillin G (100 U/ml), streptomycin
(100 U/ml), L-glutamine (2 mM), primocin (100 mg/ml) and plasmocin
(2.5 mg/ml). Raji-CD4 is an Epstein-Barr-virus-carrying B-cell line
rendered susceptible to HIV-1 infection by stable transfection with
cDNA encoding human CD4 (Tremblay et al., 1994). Raji-CD4-DCIR
cells stably expressing DCIR (wild type) were obtained following
retroviral transduction. Raji-CD4-DCIR-Y7F cell line has the tyrosine
residue in its ITIM motif replaced by phenylalanine (Lambert et al.,
2011). All Raji cells were cultured in RPMI 1640 medium supplemen-
ted with 10% FBS along with 1 mg/ml of the selective agent G418. For
all exosome production experiments, bovine exosomes were elimi-
nated from all FBS used in culture media by overnight ultracentrifuga-
tion at 100,000g. The human embryonic kidney cell line HEK 293 T
was obtained from the ATCC and maintained in α-MEM medium
supplemented with 10% FBS, penicillin G (100 U/ml), streptomycin
(100 U/ml), L-glutamine (2 mM) and geneticin (0.5 mg/ml).
Production of virus stocks
Virions were initially produced upon transient transfection of
HEK 293 T cells as described previously (Cantin et al., 1997). The
infectious molecular clones used in this study were pNL4-3 (X4-
tropic) and pNLAD8 (R5-tropic), obtained through the AIDS
Repository Reagent Program (Germantown, MD). The pNL4-
3Balenv vector was generated by replacing the env gene of the
X4-tropic HIV-1 strain NL4-3 with that of the R-5-tropic HIV-1 Bal
strain (provided by R. Pomerantz, Thomas Jefferson University,
Philadelphia, PA). All supernatants were collected and processed
by centrifuging at 300g for 5 min, ﬁltering the supernatant using
0.22 mm pore cellulose membrane (Millipore, Billerica, MA) and
centrifuging the ﬁltrate at 100,000g for 45 min at 4 1C, and
standardized for virion content based on an in-house double-
antibody sandwich enzyme-linked immunosorbent assay (ELISA)
speciﬁc for viral protein p24 (Bounou et al., 2002).
HIV-1 attachment and infection assays on iMDDCs
For assessing attachment or infection, iMDDCs (3105 cells in
a ﬁnal volume of 300 ml) were pre-treated with 1–50 mM of DCIR
inhibitor for 10 min and exposed to NL4-3Balenv (30 ng of p24) for
1 or 2 h at 37 1C. After 3 washes with PBS, cells were lysed with a
hypotonic buffer as described previously (Gilbert et al., 2002) and
the cell lysates were frozen at 20 1C before measuring the p24
contents. For infection assays, cells were maintained in complete
RPMI 1640 supplemented with GM-CSF and IL-4 in 96-well plates,
in a ﬁnal volume of 200 ml. Every three days over a nine-day
period, half of the conditioned medium was collected (replaced
with fresh medium) and kept at 20 1C until assayed.
DCIR activation with monoclonal antibody
Raji-CD4-DCIR or Raji-CD4-DCIR-Y7F cells (3106) were sus-
pended in 3 ml of RPMI 1640 supplemented with 10% FBS in assay
plate wells coated with 30 mg of monoclonal anti-DCIR antibody or
isotype control and incubated at 37 1C for 48 h. The supernatants
were then collected for exosome puriﬁcation as described above.
DCIR activation of Raji cell lines with HIV-1
Raji-CD4-DCIR and/or Raji-CD4-DCIR-Y7F cells (106 cells) were
contacted with NL4-3 (100 ng p24) for 60 min at 37 1C or for 2 h as
described in Figure legends. The virus/cell suspension was then
washed three times with PBS to remove the unbound virus and
the cells were resuspended in RPMI 1640 supplemented with 10%
exosome-depleted FBS. Fresh medium was added on day 2 and
supernatants were collected on day 5. Microvesicles and exosomes
were puriﬁed by differential centrifugation as described below and
exosomes were quantiﬁed by measuring AChE activity.
EVs and exosomes puriﬁcation
Cells were collected and processed by centrifuging at 300g for
5 min. Supernatants were ﬁltered using 0.22 mm pore cellulose
membrane (Millipore, Billerica, MA) before centrifugation at
100,000 g for 45 min at 4 1C. The pellet containing exosomes/virus
was then washed with PBS (Figs. 5 and 6, S1, S2) or not (Figs. 2–4)
and resuspended in PBS (50 ml per 3106 Raji-CD4-DCIR, 50 ml per
1106 iMDDCs).
Measurement of EVs and exosome size using the Zetasizer Nano-ZS
The 100,000g pellet obtained after ultracentrifugation was
suspended in PBS. The suspension was analyzed with the Zetasizer
Nano-ZS (Malvern, UK). The data represent an average of three
measurements performed at 4 1C.
Velocity gradient
iMDDCs from ﬁve healthy blood donors were pre-treated with
DCIR inhibitor (10 mM) for 10 min at 37 1C before contact with
NL4-3Balenv (100 ng p24/106 cells). As described in Figure legends,
the cellular supernatants were harvested after 48 h. Virions, EVs
and exosomes were ﬁrst concentrated by ultracentrifugation using
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an Optima L-90K Beckman Coulter apparatus (Fullerton, CA) for
45 min at 100,000g (31,500 rpm) in a 70 Ti rotor. The pellet
containing virions, exosomes and EVs was resuspended in 500 μl
of PBS and then centrifuged through a 6–18% Optiprep velocity
gradient as described previously (Cantin et al., 2008). Optiprep
velocity gradients were centrifuged using the Optima L-90K
apparatus for 50 min at 52,000 rpm in a NVT 65 rotor. Gradient
fractions were collected from the top. All the fractions were then
assayed for AChE activity, indicating the presence of exosomes.
Acetylcholinesterase activity assay
AChE activity was measured using a procedure described
previously (Cantin et al., 2008). Brieﬂy, 20–100 ml of sample were
added to a 1:1 mix of acetylthiocholine at a ﬁnal concentration of
1.25 mM in PBS at pH 8.0 and 5,5-dithio-bis(2-nitrobenzoic acid) at
a ﬁnal concentration of 0.1 mM in PBS at pH 7.0, and brought to a
ﬁnal volume of 200 ml. The assay was performed at room tem-
perature. Changes in absorbance were monitored at 450 nm for
10 min using a microplate spectrophotometer (ELX808, BIO-TEK
Instruments, Winooski, VT or SpectraMax 190, Molecular Devices,
Sunnyvale, CA).
SDS-PAGE and western blot analyses
Twenty-ﬁve microliter of a total volume of 100 ml of each
exosome, microvesicle or virion preparation were added to an
equal volume of modiﬁed Laemmli's 2 sample buffer and kept at
100 1C for 7 min as described previously (Gilbert et al., 2002). The
samples were then resolved by electrophoresis on a 10% SDS-
polyacrylamide gel and transferred to Immobilon PVDF mem-
branes (Millipore Corporation, Bedford, MA). Immunoblotting
was performed overnight at 4 1C using antibody diluted 1:100 to
1:200 in non-fat dry skim milk (5%) dissolved in Tris-buffered
saline/0.1%, Tween-20, and revealed using the Luminata Forte
horseradish peroxidase (HRP) substrate (Millipore Corporation,
Bedford, MA) for free exosome detection. HRP-conjugated second-
ary anti-mouse antibody was used at a dilution of 1:10,000.
Apoptosis studies and ﬂow cytometric analyses
Five microliter of the cell-permeate containing FITC-conjugated
pan-caspase inhibitor FITC-VAD-FMK were added per 5105 cells
to obtain a ﬁnal medium volume of 400 ml and cultures were
incubated for 30 min at 37 1C. Cells were then washed and
resuspended in PBS containing 2 mM EDTA/0.5% BSA and ﬁxed
with 2% p-formaldehyde (ﬁnal concentration) for subsequent
analysis by ﬂow cytometry (FACSCalibur™ platform, Becton-Dick-
inson). Data were acquired using BD CellQuest Pro software and
analysis was carried out using Cyﬂogic software. CD4TL (PHA-L/IL-
2 activated) or neutrophils were treated overnight at 37 1C with
AT-2-treated pellet containing exosomes and noninfectious HIV-1
particle preparation (25 ml) from 1.5106 live iMDDCs before
staining with FITC-VAD-FMK according to the manufacturer's
protocol.
Colorimetric reduction of thiazolyl blue tetrazolium bromide
Raji-CD4-DCIR or Raji-CD4-DCIR-Y7F were incubated or not
with 10 mM of DCIR inhibitor and cultured in 96-well plates in a
ﬁnal volume of 150 ml of RPMI 1640 (without phenol red) supple-
mented with 10% FBS for 48 h at 37 1C. Thiazolyl blue terazolium
bromide was added in each well at a ﬁnal concentration of 0.5 mg/
ml for 30 min at 37 1C before addition of lysis buffer (0.1 g/ml SDS,
0.01 M HCl). After overnight incubation at 37 1C, absorbance at
570 nm was monitored.
Tyrosine phosphorylation
Raji-CD4-DCIR cells were starved for 16 h before their resus-
pension at a concentration of 2107 cells/ml in Hank's balanced
salt solution (HBSS) containing 10 mM HEPES pH 7.4, 1,6 mM Ca2þ
and no Mg2þ . Before stimulation, cells were incubated 10 min at
37 1C before incubation with anti-DCIR antibody (5 mg/ml) for
2 min. F(ab')2 fragment goat anti-mouse F(ab')2 speciﬁc antibody
(15 mg/ml) was then added to the suspension from 30 s to 5 min.
Modiﬁed Laemmli's 2 sample buffer (40 ml) was added to stop
the reaction, as already described (Gilbert et al., 2002). Samples
were heated for 7 min at 95 1C and stored at 20 1C until further
analysis. Aliquots (50 ml) were analyzed by 7.5–20% SDS-PAGE and
transferred to Immobilon PVDF membranes. Equal protein loading
and transfer efﬁciency was visualized by Ponceau Red staining.
The membranes were blocked for 30 min in Tris-buffered saline/
0.15% (Tween 20) containing 2% (w/v) gelatin and exposed for
30 min to a monoclonal anti-phosphotyrosine antibody (4G10)
(1:4000). They were then washed twice in Tris-buffered saline/
0.15% Tween 20, incubated for 30 min with a HRP-conjugated
secondary anti-mouse antibody at a dilution of 1:20,000 and then
washed again. The membranes were revealed using Western
Lightnings Plus-ECL Enhanced Chemiluminescence Substrate
(PerkinElmer Inc., Waltham, MA).
Internalization and recycling of B2R-GFP receptor
Cell culture and treatments were conducted at 37 1C. A HEK
293 cell line stably expressing the bradykinin B2 receptor fused to
green ﬂuorescent protein (B2R-GFP) was used as a model of
endosomal cycling (Charest-Morin et al., 2013). Cells were cultured
for 2 days in complete α-MEM with geniticin 0.5 mg/ml (Life
Technologies, Burlington, ON, Canada). For B2R-GFP endocytosis,
the distribution of subcellular ﬂuorescence was observed in cells
exposed for 30 min to DCIR inhibitor or paclitaxel before 30 min of
stimulation with bradykinin. For B2R-GFP recycling, epiﬂuores-
cence was observed in cells stimulated for 30 min with bradykinin
and then exposed to cytochalasin D or DCIR inhibitor for 2.5 h.
Cells were washed with PBS before observation. An Olympus BX51
microscope coupled to a CoolSnap HQ digital camera (ﬁlters for
GFP: excitation 460–500 nm, emission 510–560 nm) was used at
100 (the 100 UplanApo oil-immersion lens) as described
previously (Charest-Morin et al., 2013). Subcellular distribution
of B2R-GFP was measured as the proportion of cells exhibiting
prominent intracellular endosomal structures labeled with the
ﬂuorescent receptor, based on a large photographic record (resting
cells generally exhibit receptors associated with the plasma
membrane only). Values were reported as mean7SEM and
statistically analyzed by ANOVA test.
Statistical analyses
Means were compared using either Student's t test or a single-
factor ANOVA followed by Dunnett multiple comparisons when
more than two treatment means were considered. P values of less
than 0.05 were deemed statistically signiﬁcant. Calculations were
performed using GraphPad Prism software (GraphPad Software, La
Jolla, CA).
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